Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 2 PK dosing results. PK dosing results. (A) Plasma concentration of hPTH(1–34) versus time after release of 40-μg dose from implanted microchip device.

Published byHengki Kusuma Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 2 PK dosing results. PK dosing results. (A) Plasma concentration of hPTH(1–34) versus time after release of 40-μg dose from implanted microchip device."— Presentation transcript:

1 Fig. 2 PK dosing results. PK dosing results. (A) Plasma concentration of hPTH(1–34) versus time after release of 40-μg dose from implanted microchip device for the seven study patients. (B) Plasma concentration of hPTH(1–34) versus time after injection of 20- and 40-μg doses of FORSTEO for the seven study patients. The 40-μg doses were administered as two sequential 20-μg injections. (C) Mean plasma concentration of hPTH(1–34) versus time after release of 40-μg dose from the implanted microchip device (n = 7 patients × four doses) and injection of 2 × 20–μg doses of FORSTEO (n = 7 patients × two doses). Data are means ± SD. Robert Farra et al., Sci Transl Med 2012;4:122ra21 Copyright © 2012, American Association for the Advancement of Science

Download ppt "Fig. 2 PK dosing results. PK dosing results. (A) Plasma concentration of hPTH(1–34) versus time after release of 40-μg dose from implanted microchip device."

Similar presentations

First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip by Robert Farra, Norman F. Sheppard, Laura McCabe, Robert M. Neer, James M. Anderson,

First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip by Robert Farra, Norman F. Sheppard, Laura McCabe, Robert M. Neer, James M. Anderson,
Soft robotic device applied to the RV in a pressure overload model of RHF. Soft robotic device applied to the RV in a pressure overload model of RHF. (A.

Soft robotic device applied to the RV in a pressure overload model of RHF. Soft robotic device applied to the RV in a pressure overload model of RHF. (A.
Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.
Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.
Fig. 4. Local application of FR provides prolonged protection against Gq-dependent airway constriction in normal and OVA-sensitized mice in vivo. Local.

Fig. 4. Local application of FR provides prolonged protection against Gq-dependent airway constriction in normal and OVA-sensitized mice in vivo. Local.
Fig. 4. Clearance of 12-mer-1 from a nonhuman primate model.

Fig. 4. Clearance of 12-mer-1 from a nonhuman primate model.
Fig. 2. CD treatment facilitates regression of murine atherosclerosis.

Fig. 2. CD treatment facilitates regression of murine atherosclerosis.
Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.

Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.
Fig. 5 Quantitative assessment of the efficacy of the tissue-engineered implant to heal the TMJ disc defect. Quantitative assessment of the efficacy of.

Fig. 5 Quantitative assessment of the efficacy of the tissue-engineered implant to heal the TMJ disc defect. Quantitative assessment of the efficacy of.
Fig. 1 ZIKV RNA in blood and tissues.

Fig. 1 ZIKV RNA in blood and tissues.
Consolidated Standards of Reporting Trials flow diagram of VRC trial

Consolidated Standards of Reporting Trials flow diagram of VRC trial
Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.
Filipin staining of marginal gyrus of cerebral cortex in NPC cats

Filipin staining of marginal gyrus of cerebral cortex in NPC cats
Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.

Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.
Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.
Fig. 3. Comparison of prediction performance.

Fig. 3. Comparison of prediction performance.
Fig. 7 Bacterial dependency networks in IgA deficiency and HDs.

Fig. 7 Bacterial dependency networks in IgA deficiency and HDs.
Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.

Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.
Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.

Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.
Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Similar presentations

Ads by Google